Advertisement
Astra Zeneca
Subscribe to Astra Zeneca

The Lead

Off-Label Prescribing of Antipsychotic Drug Highlights Lack of Oversight

October 22, 2014 8:38 am | by Adam Miller, The Canadian Press | News | Comments

An increase in the number of prescriptions of a powerful antipsychotic drug for conditions not approved by Health Canada is raising concern about what medical experts call lack of professional and government oversight of doctors' prescribing practices.

MedImmune Receives FDA Fast Track Designation for Development of MEDI3902 for Prevention of Nosocomial Pneumonia

September 23, 2014 8:22 am | News | Comments

AstraZeneca announced today that its global biologics research and development arm, MedImmune,...

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293,...

AstraZeneca and Redx Pharma to Collaborate on Targeting Genetic Drivers of Tumor Growth

September 3, 2014 8:54 am | News | Comments

AstraZeneca has entered into a research collaboration with Redx Pharma Limited to discover and...

View Sample

FREE Email Newsletter

UK High Court Gives Positive Judgment in Teva's Patent Case Against AstraZeneca

September 3, 2014 8:33 am | News | Comments

Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.

DOJ Closes Probe Into AstraZeneca Trial

August 19, 2014 4:37 pm | by Associated Press | News | Comments

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.                

AstraZeneca Advances Tralokinumab for Severe Asthma to Phase III

August 14, 2014 8:32 am | News | Comments

AstraZeneca announced the start of the Phase III program for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.  

Advertisement

AstraZeneca Announces Results of Phase III Gout Treatment Trial

August 13, 2014 8:46 am | News | Comments

AstraZeneca today announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), as a combination therapy for the treatment of patients with symptomatic gout.

AstraZeneca and Kyowa Hakko Kirin Partner on Immuno-Oncology Clinical Study

July 30, 2014 10:02 am | News | Comments

AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

AstraZeneca to Acquire Almirall's Respiratory Disease Business

July 30, 2014 8:11 am | News | Comments

AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.

AstraZeneca and QIAGEN to Develop Diagnostic Test for Lung Cancer Patients Suitable for Treatment with IRESSA

July 28, 2014 8:49 am | News | Comments

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.  

AstraZeneca and Roche to Develop Companion Diagnostic Test for AZD9291

July 28, 2014 7:57 am | News | Comments

AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).

Advertisement

Obama Wants Limits on US Company Mergers Abroad

July 25, 2014 8:32 am | News | Comments

Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.      

MedImmune and Advaxis Partner on Immuno-Oncology Combination Clinical Trial

July 22, 2014 8:20 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.    

AstraZeneca Reveals Designs For New R&D Center & Corporate HQ In Cambridge, UK

July 18, 2014 9:08 am | by AstraZeneca | News | Comments

AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.

AstraZeneca and Max Planck Institute to Create Satellite Chemistry Unit for Cardiovascular and Metabolic Diseases

July 8, 2014 8:47 am | News | Comments

AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

Panel: Flu Spray Better Than Shots for Young Kids

June 26, 2014 8:30 am | by MIKE STOBBE, AP Medical Writer | News | Comments

When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children. The advisory panel voted Wednesday to advise doctors that FluMist nasal spray is a bit better at preventing flu in healthy young kids.

Advertisement

AstraZeneca Licenses Synairgen's Asthma Therapy for $225M

June 13, 2014 8:43 am | News | Comments

Under the terms of the exclusive license agreement, AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and commercial milestones of up to $225 million. In addition, AstraZeneca will pay tiered royalties ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs.

Isis Pharmaceuticals Earns $15M from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx

June 10, 2014 8:21 am | News | Comments

Isis Pharmaceuticals announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with cancer.  Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-ARRx. ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR).

AstraZeneca’s Novel Antibiotic Candidate AZD0914 Given Fast Track Status by FDA

June 3, 2014 8:04 am | News | Comments

AstraZeneca today announced that the FDA has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development program Fast Track status for the treatment of uncomplicated gonorrhea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.

Actavis Confirms Generic Onglyza Patent Challenge

May 28, 2014 9:05 am | News | Comments

Actavis has filed an Abbreviated New Drug Application with the FDA seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza. 

Pfizer Pulls Plug on Push to Buy AstraZeneca

May 26, 2014 11:30 am | by Alex Veiga - AP Business Writer - Associated Press | News | Comments

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history. The announcement came a week after AstraZeneca's board rejected a $119 billion buyout proposal from Pfizer.

Another AstraZeneca Shareholder Voices Criticism

May 21, 2014 2:13 pm | News | Comments

Another AstraZeneca shareholder has criticized the pharmaceutical company's handling of Pfizer's $119 billion takeover bid, saying Wednesday it was "arguably wrong" to reject it so quickly.          

AstraZeneca Shareholder Urges Pfizer Rethink

May 20, 2014 9:02 am | News | Comments

AstraZeneca shareholder Schroders has urged the pharmaceutical firm to reconsider its rejection of a takeover offer from U.S. drugmaker Pfizer. The fund manager, which holds a 2 percent stake in AstraZeneca, is the biggest shareholder to call publicly for renewed takeover talks.

AstraZeneca Board Rejects New Offer from Pfizer

May 19, 2014 7:59 am | by GREGORY KATZ, Associated Press; LINDA A. JOHNSON, Associated Press | News | Comments

The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that has caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

As Pfizer Fights it Out in Britain, US Lawmakers are Making Their Move in the Long Game

May 16, 2014 9:03 am | by Brian Williamson, Managing Director, Jumpstart | Blogs | Comments

While British attention in the Pfizer-AstraZeneca takeover battle has been focused on clashes between MPs and Pfizer chief executive Ian Read, events have been unfolding across the Atlantic which could have an infinitely greater bearing on where the pharma giant eventually conducts its business.

Pfizer's Troubles Across the Pond

May 15, 2014 8:51 am | Videos | Comments

Why are British protectionists trying to block a proposed pharmaceutical merger?                             

Pfizer Chief Says Jobs Will Go in Takeover

May 13, 2014 1:48 pm | by DANICA KIRKA, Associated Press | News | Comments

Pfizer Inc.'s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses — but promised to keep key research jobs in Britain as part of its $106 billion takeover bid.       

Lawmakers Press Pfizer CEO for Job Guarantees

May 13, 2014 7:58 am | by DANICA KIRKA, Associated Press | News | Comments

British lawmakers pressed the chief executive of Pfizer on Tuesday to guarantee jobs should the American company succeed in taking over London-based AstraZeneca, prodding him on whether he could be trusted to honor promises made as part of the bid.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading